Verdinexor: A new oral treatment option for canine lymphoma

1 hour of CE Credit

In this CE session, we’ll review the latest best practices for managing canine lymphoma. We’ll also talk about how the first FDA conditionally approved oral tablet for canine lymphoma, LAVERDIA™-CA1 (verdinexor), is giving veterinarians and dog owners more options and increasing access to cancer care.

What you'll learn:

  • Evolving protocols for canine lymphoma treatment

  • The role of primary care teams in treating lymphoma

  • How SINE drugs work and why they are different

  • When to consider LAVERDIA™-CA1 for lymphoma patients

  • Guidelines to optimize patient outcomes

This program has been approved for 1 hour of continuing education credit in jurisdictions that recognize RACE approval.
Anivive Logo